title: Decline in motor functions in aging is related to the loss of NMDA receptors.
abstract: The aim of the study was to assess the contribution of central dopaminergic and glutamatergic systems to the age-dependent loss of motor functions in rats. Rats of three age groups were compared: young (3-5-month-old), middle-aged (20-21-month-old) and old (29-31-month-old). The obtained results showed an age-dependent decline in the electromyographic (EMG) resting and reflex activities in the gastrocnemius and tibialis anterior muscles, as well as in the T-maze performance. Although these disturbances were accompanied with significant age-dependent decreases in the binding to NMDA, AMPA and dopamine D2 receptors, and a decline in the number of nigral dopamine neurons, they were significantly correlated with the loss of the binding to NMDA receptors only. The reduction in T-maze performance with aging was additionally correlated with a decrease in motor functions (EMG activity). The study suggests a crucial role of the loss of NMDA receptors in age-dependent motor disabilities, as well as in disturbances measured in the T-maze.
authors: Department of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna St., 31-343, Kraków, Poland. ossowska@if-pan.krakow.pl
authors: K
authors: K
authors: Ossowska
authors: S
authors: S
authors: Wolfarth
authors: G
authors: G
authors: Schulze
authors: J
authors: J
authors: Wardas
authors: M
authors: M
authors: Pietraszek
authors: E
authors: E
authors: Lorenc-Koci
authors: M
authors: M
authors: Smiałowska
authors: H
authors: H
authors: Coper
mesh_terms: D000375:Aging / Q000378:metabolism* / Q000523:psychology; D000818:Animals; D000843:Ankle Joint / Q000503:physiopathology; D015415:Biomarkers; D001696:Biomechanical Phenomena; D001931:Brain Mapping; D002452:Cell Count; D016291:Dizocilpine Maleate / Q000378:metabolism; D004298:Dopamine / Q000502:physiology*; D004576:Electromyography; D005260:Female; D018698:Glutamic Acid / Q000502:physiology*; D007859:Learning Disabilities / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D018782:Maze Learning; D009069:Movement Disorders / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D018482:Muscle, Skeletal / Q000378:metabolism / Q000503:physiopathology; D009419:Nerve Tissue Proteins / Q000032:analysis* / Q000502:physiology; D018583:Pliability; D011597:Psychomotor Performance; D020891:Raclopride / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time; D018091:Receptors, AMPA / Q000032:analysis / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000032:analysis / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000032:analysis* / Q000378:metabolism / Q000502:physiology; D013378:Substantia Nigra / Q000378:metabolism / Q000473:pathology; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000378:metabolism
chemical_list: D015415:Biomarkers; D009419:Nerve Tissue Proteins; D018091:Receptors, AMPA; D017448:Receptors, Dopamine D2; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D020891:Raclopride; D016291:Dizocilpine Maleate; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine